Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quest launches molecular cervical cancer TERC test
The cervical cancer TERC test helps identify women with high chance of developing malignancy if not treated. Quest Diagnostics cancer diagnostics services medical director Daniel Jones said that
The cervical cancer TERC test helps identify women with high chance of developing malignancy if not treated. Quest Diagnostics cancer diagnostics services medical director Daniel Jones said that
Ballesteros, who has joined the company in 2004, held key management positions within the company since then. Previously, Ballesteros served Sensient Colors as general manager, where he was
Pluristem earlier received an orphan drug status from the FDA for its PLX cell therapy in the treatment of Buerger’s disease and the new filing marks the company’s
The adjuvanted RiVax was found to be safe and well tolerated in the study, conducted in healthy volunteers, and induced better ricin neutralising antibody levels in humans compared
Irbesartan, a generic version of Aprovel (Irbesartan) by Sanofi Pharma Bristol-Myers Squibb SNC, is indicated to treat essential hypertension and renal disease in patients with hypertension and type
Daratumumab is a human CD38 monoclonal antibody which is currently in Phase I/II studies in relapsed, refractory multiple myeloma and is expected to have potential in other cancer
Under the agreement, Acceleron will initially use DocCompliance in its research and development group to provide users with a secure, structured, and controlled environment in the Cloud. The
The oral multi-kinase inhibitor regorafenib is used for the treatment of metastatic and unresectable gastrointestinal stromal tumors (GIST) in pre treated patients with advance in disease. The application
The partnership will facilitate both the companies to develop new products and allow Life Technologies to distribute Sino Biological’s recombinant proteins, antibodies and Elisa kits. Life Technologies expects
The company will shell out $181m to the participating states accordingly to resolve state consumer protection law claims, according to Janssen. All parties including Janssen have defended the